NCT02309762View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Healthy
Interventions
DRUG

FB825

FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection

DRUG

Placebo

Solution containing no active ingredients

Sponsors
All Listed Sponsors
lead

Fountain Biopharma Inc.

INDUSTRY

NCT02309762 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers | Biotech Hunter | Biotech Hunter